Liver Cancer
Copyright ©The Author(s) 2004. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 1, 2004; 10(1): 46-52
Published online Jan 1, 2004. doi: 10.3748/wjg.v10.i1.46
Potential role of p53 mutation in chemical hepatocarcinogenesis of rats
Wei-Guo Deng, Yan Fu, Yu-Lin Li, Toshihiro Sugiyama
Wei-Guo Deng, Department of Nutrition and Food Hygiene, School of Public Health, Jilin University, Changchun 130021, Jilin Province, China
Yan Fu, Department of Obstetrics and Gynecology, First Hospital, Jilin University, Department of Pathology, School of Preclinical Medicine, Jilin University, Changchun 130021, Jilin Province, China
Yu-Lin Li, Department of Pathology, School of Preclinical Medicine, Jilin University, Changchun 130021, Jilin Province, China
Toshihiro Sugiyama, Department of Biochemistry, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan
Author contributions: All authors contributed equally to the work.
Supported by Jilin University Excellent Young Teacher Foundation, No. 2001033
Correspondence to: Dr. Yan Fu, Department of Obstetrics and Gynecology, First Hospital, Jilin University, 1 Xinmin Street, Changchun 130021, Jilin Province, China
Telephone: +86-431-5612482
Received: June 5, 2003
Revised: July 20, 2003
Accepted: August 16, 2003
Published online: January 1, 2004
Abstract

AIM: Inactivation of p53 gene is one of the most frequent genetic alterations in carcinogenesis. The mutation status of p53 gene was analyzed, in order to understand the effect of p53 mutation on chemical hepatocarcinogenesis of rats.

METHODS: During hepatocarcinogenesis of rats induced by 3’-methyl-4- dimethylaminoazobenzene (3’-Me-DAB), prehepatocarcinoma and hepatocarcinoma foci were collected by laser capture microdissection (LCM), and quantitatively analyzed for levels of p53 mRNA by LightCyclerTM real-time RT-PCR and for mutations in p53 gene exons 5-8 by direct sequencing.

RESULTS: Samples consisting of 44 precancerous foci and 24 cancerous foci were collected by LCM. A quantitative analysis of p53 mRNA showed that p53 mRNA peaked at an early stage (week 6) in the prehepatocarcinoma lesion, more than ten times that of adjacent normal tissue, and gradually decreased from week 6 to week 24. The expression of p53 mRNA in adjacent normal tissue was significantly lower than that in prehepatocarcinoma. Similar to prehepatocarcinoma, p53 mRNA in cancer was markedly higher than that in adjacent normal tissue at week 12, and was closer to normal at week 24. Direct p53 gene sequencing showed that 35.3% (24/68) (9 precancer, 15 cancer) LCM samples exhibited point mutations, 20.5% of prehepatocarcinoma LCM samples presented missense mutations at exon 6/7 or/and 8, and was markedly lower than 62.5% of hepatocarcinoma ones (P < 0.01). Mutation of p53 gene formed the mutant hot spots at 5 codons. Positive immunostaining for p53 protein could be seen in prehepatocarcinoma and hepatocarcinoma foci at 24 weeks.

CONCLUSION: p53 gene mutation is present in initial chemical hepatocarcinogenesis, and the mutation of p53 gene induced by 3’-Me-DAB is an important factor of hepatocarcinogenesis.

Keywords: $[Keywords]